Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-22T01:54:39.274Z Has data issue: false hasContentIssue false

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

Published online by Cambridge University Press:  02 December 2014

Gary Hunter*
Affiliation:
Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Chris Voll
Affiliation:
Department of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Christopher A. Robinson
Affiliation:
Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
*
Royal University Hospital, Dept of Neurology, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Communications
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1. Cranmer, LD, Hersh, E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 2007;25(7): 61331.Google Scholar
2. Attia, P, Phan, GQ, Maker, AV, Robinson, MR, Quezado, MM, Yang, JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol. 2005;23(25):604353.CrossRefGoogle ScholarPubMed
3. Ribas, A, Camacho, LH, Lopez-Berestein, G, Pavlov, D, Bulanhagui, CA, Millham, R, et al. Antitumor activity in melanoma and antiself responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23(35):896877.CrossRefGoogle Scholar
4. Tchekmedyian, S, Glasby, J, Korman, A, Keler, T, Deo, Y, Davis, T. MDX-010 (human anti-CTLA-4): a phase I trial in malignant melanoma. [abstract] Proc Am Soc Clin Oncol. 2002; 2:56.Google Scholar
5. Phan, GQ, Haworth, LR, Duray, PH, Davis, TA, Rosenberg, SA. Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression. [abstract] Proc Am Soc Clin Oncol. 2003; 22: 3424.Google Scholar
6. Maker, AV, Phan, GQ, Attia, P, Yang, JC, Sherry, RM, Topalian, SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005, 12(12), 100516.CrossRefGoogle ScholarPubMed
7. Weber, J. Review: Anti-CTLA-4 Antibody Ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist. 2007;12:86472.CrossRefGoogle ScholarPubMed
8. Beck, KE, Blansfield, JA, Tran, KQ, Feldman, AL, Hughes, MS, Royal, RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte associated antigen 4. J Clin Oncol. 2006;24:22839.Google Scholar
9. Colucci, F, Bergman, ML, Penha-Goncalves, C, Cilio, CM, Holmberg, D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc Natl Acad Sci USA. 1997;94:86704.Google Scholar
10. Greve, B, Vijayakrishnan, L, Kubal, A, Sobel, RA, Peterson, LB, Wicker, LS, et al. The diabetes susceptibility locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis. J Immunol. 2004;73:15763.CrossRefGoogle Scholar
11. Ueda, H, Howson, JM, Esposito, L. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:50611.CrossRefGoogle ScholarPubMed
12. Wang, HB, Shi, FD, Li, H, Chambers, BJ, Link, H, Ljunggren, HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol. 2001;166 (10):64306.CrossRefGoogle ScholarPubMed